Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Functional fitness of CAR-T cells in the bone marrow following anti-BCMA durcabtagene autoleucel (PHE885) therapy correlate with prolonged PFS in RRMM

View Full Paper
Ask AI
Bookmark
Share

Authors

LPLakshmi Bhavani PotluriHSHannah SeahSVSahan D. Vangala

Discussion

Loading...

Member takes

Overview

Analysis reveals CAR-T cells show improved activation and less apoptosis in bone marrow, suggesting implications for disease control.

Key Points

  • Higher levels of IL-2 and granzyme-B in CAR+ T cells correlate with better patient outcomes in bone marrow.
  • CD38, CD28, and CD27 activation markers significantly differ in CAR+ T cells from patients achieving sustained complete response.
  • Observational analysis involved immune-monitoring of CAR-T cell activity in the bone marrow microenvironment after therapy infusion.
  • Findings indicate CAR-T cells exhibit enhanced anti-tumor activity and apoptosis resistance, linked to longer progression-free survival.

Cite This Study

Potluri et al. (2025) studied this question.

synapsesocial.com/papers/69362f484fa91c937236d676https://doi.org/10.1182/blood-2025-5713
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Long-term follow-up of patients with relapsed/refractory multiple myeloma after BCMA CAR-T-cell therapy2025 · 3 citations
  2. 2Assessment of long-term persistence and phenotypic features of BCMA CAR-T cells in patients with relapsed or refractory multiple myeloma treated with ciltacabtagene autoleucel.2026
  3. 3The dynamic landscape of immune environment for MM patients receiving T cell redirectiing therapies2025
  4. 4Single-cell immune profiling reveals enhanced immune fitness of endogenous and engineered T cells in patients with high-risk smoldering myeloma compared to Relapsed/Refractory myeloma following bispecific antibodies or CAR-T cell therapies.2025
  5. 5BCMA-CART therapy in 29 cases of relapsed or refractory multiple myeloma:a retrospective study2025